CurrentEndo — Lipids & metabolic liver disease

Cross-national associations of atherogenic index of plasma and frailty with cardiometabolic multimorbidity: evidence from China, England, and Europe

2026-11-13T18:46:09.627Z

Cohort study · Diabetes Res Clin Pract, 2026.

Effects of Time-Restricted Eating on Nonalcoholic Fatty Liver Disease: The TREATY-FLD Randomized Clinical Trial

2026-11-13T11:00:06.281Z

Randomized controlled trial · JAMA Netw Open, 2023. Change in IHTG content, 12 months: TRE 6.9% (95% CI -8.8% to -5.1%) · DCR 7.9% (95% CI -9.7% to -6.2%)

Postprandial triglycerides and fibroblast growth factor 19 as potential screening tools for paediatric non‐alcoholic fatty liver disease

2026-11-13T10:54:04.269Z

Diagnostic or prognostic study · Pediatr Obes, 2023. 4 h TG, 4 h post-meal: NAFLD 197 ± 69 mg/dL · OB 157 ± 72 mg/dL · NW 105 ± 45 mg/dL

Genetically predicted visceral adipose tissue and risk of nine non-tumour gastrointestinal diseases: evidence from a Mendelian randomization study

2026-11-13T10:51:50.896Z

Research article · Int J Obes (Lond), 2023. Risk of nine non-tumour gastrointestinal diseases — Higher VAT: OR 1.21 (95% CI 1.09-1.34); P = 3.06 × 10-4; Gastro-oesophageal reflux disease (GORD)

Hepatic and serum branched‐chain fatty acid profile in patients with nonalcoholic fatty liver disease: A case–control study

2026-11-13T10:47:54.884Z

Case-control study · Obesity (Silver Spring), 2023. Hepatic branched-chain fatty acids (BCFAs) significantly increased in NAFLD vs no NAFLD

Metabolic profiling of MRI ‐measured liver fat in the UK Biobank

2026-11-13T10:47:54.884Z

Cohort study · Obesity (Silver Spring), 2023. Metabolite associations with liver fat: Metabolites positively associated with liver fat after accounting for confounders, particularly extremely large and very large lipoprotein particles, VLDL TG, small HDL particles, glycoprotein acetyls, monounsaturated and saturated fatty acids, amino acids p < 0.0001 for 152 traits

A prolonged fast improves overnight substrate oxidation without modulating hepatic glycogen in adults with and without nonalcoholic fatty liver: A randomized crossover trial

2026-11-13T10:47:54.884Z

Randomized controlled trial · Obesity (Silver Spring), 2023. Nocturnal substrate oxidation, overnight — 16-hour fast vs 9.5-hour fast; intervention × time, p < 0.005 for carbohydrate and fat oxidation; lower carbohydrate and higher fat oxidation with extended fast, in both NAFL and controls

Early origins of metabolic and overall health in young adults: An outcome-wide analysis in a general cohort population

2026-11-13T10:39:51.606Z

Cohort study · Diabetes Metab, 2022. Associations of extreme BW with adult outcomes (RR [95% CI]) — LBW: RR 1.33 (95% CI 1.16;1.52); men; fasting glucose impairment

Low levels of osteocalcin, but not CTX or P1NP, are associated with nonalcoholic hepatic steatosis and steatohepatitis

2026-11-13T10:39:51.606Z

Cohort study · Diabetes Metab, 2022. median 26.4 months — Osteocalcin: OR 0.755 (95% CI 0.668; 0.855); P < 0.001; independent predictor; CTX and P1NP not

Association between liver fibrosis and decreased myocardial mechano-energetic efficiency in individuals with different degree of glucose tolerance

2026-11-13T10:35:20.262Z

Cross-sectional study · Diabetes Res Clin Pract, 2023. Myocardial MEEi: Graded decrease in MEEi with higher risk of liver fibrosis vs lowest risk

Hypertriglyceridemic waist phenotype, hypertriglyceridemic waist-to-height ratio phenotype and abnormal glucose metabolism in adolescents

2026-11-13T10:35:20.262Z

Cross-sectional study · Diabetes Res Clin Pract, 2023. Abnormal glucose metabolism: Without HW phenotype 22.7% · HW phenotype 40.6% · Without HWHtR phenotype 22.4% · HWHtR phenotype 38.6%

Changes in high-density lipoprotein cholesterol with risk of Cardiovascular Disease among initially high-density lipoprotein-high participants

2026-11-13T10:28:29.610Z

Cohort study · Cardiovasc Diabetol, 2023. Incident CVD — Greatest HDL-C increase vs Lowest HDL-C increase: aHR 1.15 (95% CI 1.05-1.25)

Sexual dimorphism in selenium deficiency is associated with metabolic syndrome and prevalence of heart disease

2026-11-13T10:28:29.610Z

Cross-sectional study · Cardiovasc Diabetol, 2023. Sex-selenium interaction with BMI, diabetes and myocardial infarction (MI), baseline: PREVEND 85.7 μg/L; BMI pinteraction < 0.001; diabetes pinteraction 0.040; MI pinteraction 0.021 · BIOSTAT-CHF 89.1 μg/L; BMI pinteraction 0.021; diabetes pinteraction 0.024; MI pinteraction 0.084

Triglyceride-glucose index and triglyceride to high-density lipoprotein cholesterol ratio as potential cardiovascular disease risk factors: an analysis of UK biobank data

2026-11-13T10:28:29.610Z

Cohort study · Cardiovasc Diabetol, 2023. Total CVD, median follow-up 8.1 years — TyG Q2 vs TyG Q1: multivariable-adjusted HR 1.05

Associations of liver fat content with cardiometabolic phenotypes and outcomes in a multi‐ethnic population: Results from the Dallas Heart Study

2026-11-13T10:20:05.638Z

Cohort study · Diabetes Obes Metab, 2022. Cardiometabolic biomarkers across liver fat quintiles, baseline: Body mass index (BMI), waist circumference, hypertension, diabetes, cholesterol, TG, hs-CRP, leptin, fasting glucose, HOMA-IR, coronary artery calcium, visceral, abdominal and lower body subcutaneous adipose tissue worsened across liver fat quintiles P < 0.0001

Burden of liver complications related to non‐alcoholic fatty liver disease in China from 2005 to 2019: Observations from the Global Burden of Disease Study, 2019

2026-11-13T10:20:05.638Z

Secondary analysis · Diabetes Obes Metab, 2023. LC-NAFLD burden in China, 2019: LC-NAFLD cases 293.42 million (95% UI 263.69-328.44)

Hepatic steatosis and advanced hepatic fibrosis are independent predictors of long‐term mortality in acute myocardial infarction

2026-11-13T10:20:05.638Z

Cohort study · Diabetes Obes Metab, 2023. All-cause mortality: Hepatic steatosis 24.6% · No hepatic steatosis 20.9% · Advanced fibrosis 45.6% · No advanced fibrosis 32.9%

A Meta-analysis on Associated Risk of Mortality in Nonalcoholic Fatty Liver Disease

2026-11-13T10:04:31.875Z

Meta-analysis · Endocr Pract, 2022. Mortality — NAFLD vs Non-NAFLD: HR (all-cause mortality) 1.32 (95% CI 1.09-1.59); P < .01; I2 = 96.00%

Association of serum uric acid with all‐cause and cardiovascular mortality among adults with nonalcoholic fatty liver disease

2026-11-13T09:59:57.591Z

Cohort study · Clin Endocrinol (Oxf), 2022. CVD mortality per SD μmol/L SUA increment, mean follow-up 8.3 years — NAFLD: per SD μmol/L SUA increment: aHR 1.40 (95% CI 1.16-1.68)

A Low-Frequency APOB p.(Pro955Ser) Variant Contributes to the Severity of/Variability in Familial Hypercholesterolemia

2026-11-13T09:55:31.327Z

Research article · J Clin Endocrinol Metab, 2022. Allele frequency of APOB c.2863C > T:p.(Pro955Ser): HeFH probands 0.15 · General Japanese population 0.034

Nonalcoholic Fatty Liver Disease and Adverse Pregnancy Outcomes in Women With Normal Prepregnant Weight

2026-11-13T09:55:31.327Z

Cohort study · J Clin Endocrinol Metab, 2022. Adverse pregnancy outcomes (fully adjusted) — NAFLD vs No NAFLD: aOR, GDM 2.477 (95% CI 1.885-3.254)

Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial

2026-11-13T09:54:14.154Z

Randomized controlled trial · Lancet Diabetes Endocrinol, 2023. Percentage change in LDL cholesterol, day 210: Inclisiran-only 47.5% (95% CI 50.7-44.3)

Risks and burdens of incident dyslipidaemia in long COVID: a cohort study

2026-11-13T09:54:14.154Z

Cohort study · Lancet Diabetes Endocrinol, 2023. Incident dyslipidaemia (post-acute phase), 1 year — COVID-19 vs Contemporary control: HR 1.26 (95% CI 1.22-1.29); total cholesterol >200 mg/dL

Bariatric–metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial

2026-11-13T05:27:17.009Z

Randomized controlled trial · Lancet, 2023. NASH resolution without worsening of fibrosis, 1 year: RYGB 54 (56%) · SG 55 (57%) · Lifestyle modification 15 (16%)

Association of polycyclic aromatic hydrocarbons with systemic inflammation and metabolic syndrome and its components

2026-11-13T05:21:31.812Z

Cross-sectional study · Obesity (Silver Spring), 2023. MetS in adults, OR per one-unit increase in log-transformed urinary PAH metabolite level: 1-OHNa, OR 1.11 (1.03-1.20) (95% CI)

Causal effect of adiposity on the risk of 19 gastrointestinal diseases: a Mendelian randomization study

2026-11-13T05:21:31.812Z

Research article · Obesity (Silver Spring), 2023. GI diseases per 1-SD increase in genetically predicted BMI (4.77 kg/m2) or WC (12.52 cm) — BMI per 1-SD increase: OR 1.22 (95% CI 1.12-1.34); p < 0.0001; Nonalcoholic fatty liver disease (NAFLD)

Rising NAFLD and metabolic severity during the Sars‐CoV‐2 pandemic among children with obesity in the United States

2026-11-13T05:21:31.812Z

Cross-sectional study · Obesity (Silver Spring), 2023. NAFLD prevalence (MRI proton density fat fraction (PDFF) ≥ 5.5%): Before pandemic 36.2% · During pandemic 60.9%

Modification of the all-cause and cardiovascular disease related mortality risk with changes in the metabolic syndrome status: a population-based prospective cohort study in Taiwan

2026-11-13T05:16:25.392Z

Cohort study · Diabetes Metab, 2022. MetS-recovered vs MetS-persistent: aHR 0.87 (95% CI 0.82-0.92); all-cause mortality

Noninvasive identification of probable fibrotic nonalcoholic steatohepatitis across the spectrum of glucose tolerance in the United States

2026-11-13T05:13:07.965Z

Cross-sectional study · Diabetes Res Clin Pract, 2023. Probable fibrotic NASH prevalence: Overall prevalence of probable fibrotic NASH 5.9 % (95 % CI 5.2-6.7)

Remnant cholesterol has a non-linear association with non-alcoholic fatty liver disease

2026-11-13T05:13:07.965Z

Cross-sectional study · Diabetes Res Clin Pract, 2023. Positive relationship between RC and NAFLD after adjusting for confounders

Non‐fasting lipids and cardiovascular disease in those with and without diabetes in Alberta's Tomorrow Project: A prospective cohort study

2026-11-13T05:10:47.230Z

Cohort study · Diabet Med, 2023. Incident CVD per non-fasting RC — No diabetes: aHR 1.22 (95% CI 1.03-1.43); p = 0.02; RC associated with increased CVD risk

Association between triglyceride-glucose index and all-cause mortality in critically ill patients with ischemic stroke: analysis of the MIMIC-IV database

2026-11-13T05:07:38.642Z

Cohort study · Cardiovasc Diabetol, 2023. All-cause mortality by TyG index: Hospital mortality, overall cohort 19.0%

Association between triglyceride glucose index and arterial stiffness and coronary artery calcification: a systematic review and exposure-effect meta-analysis

2026-11-13T05:07:38.642Z

Meta-analysis · Cardiovasc Diabetol, 2023. Arterial stiffness, category analysis: OR 1.83 (95% CI 1.55-2.17, I2 = 68%)

Association between the triglyceride glucose index and in-hospital and 1-year mortality in patients with chronic kidney disease and coronary artery disease in the intensive care unit

2026-11-13T05:07:38.642Z

Cohort study · Cardiovasc Diabetol, 2023. Median TyG index 9.1 [8.6,9.5]

Association between the triglyceride-glucose index and the presence and prognosis of coronary microvascular dysfunction in patients with chronic coronary syndrome

2026-11-13T05:07:38.642Z

Cohort study · Cardiovasc Diabetol, 2023. MACE in CMD patients, follow-up: T3 39.2%

Association between triglyceride-glucose index trajectories and carotid atherosclerosis progression

2026-11-13T05:07:38.642Z

Cohort study · Cardiovasc Diabetol, 2023. CAS progression, median follow-up 757 days — Moderate-stable vs Low-stable: HR 1.139 (95% CI 1.021-1.272); multivariate adjusted

Association of dynamic change of triglyceride-glucose index during hospital stay with all-cause mortality in critically ill patients: a retrospective cohort study from MIMIC IV2.0

2026-11-13T05:07:38.642Z

Cohort study · Cardiovasc Diabetol, 2023. 1-year all-cause mortality, 1 year: Deaths within first year 2477 (29.52%)

Long- and very long-chain ceramides are predictors of acute kidney injury in patients with acute coronary syndrome: the PEACP study

2026-11-13T05:07:38.642Z

Cohort study · Cardiovasc Diabetol, 2023. AKI, during hospitalisation — Cer(d18:1/24:2) Q4 vs Q1: OR 3.503 (95% CI 1.743-7.040); P < 0.001; risk-factor adjusted; highest OR among ceramides

Predicting long-term prognosis after percutaneous coronary intervention in patients with new onset ST-elevation myocardial infarction: development and external validation of a nomogram model

2026-11-13T05:07:38.642Z

Cohort study · Cardiovasc Diabetol, 2023. Nomogram discrimination (Harrell's C-index); nomogram variables: age, DM, current smoking, triglyceride glucose (TyG) index: Development 0.772 (95% CI 0.721-0.823); Harrell's C-index 0.772 · Validation 0.736 (95% CI 0.656-0.816); Harrell's C-index 0.736

The predictive value of atherogenic index of plasma for cardiovascular outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention with LDL-C below 1.8mmol/L

2026-11-13T05:07:38.642Z

Cohort study · Cardiovasc Diabetol, 2023. MACCE, median follow-up 26 months: High AIP 9.6% · Low AIP 6.0%

The synergistic effect of the triglyceride-glucose index and serum uric acid on the prediction of major adverse cardiovascular events after coronary artery bypass grafting: a multicenter retrospective cohort study

2026-11-13T05:07:38.642Z

Cohort study · Cardiovasc Diabetol, 2023. MACE, follow-up: Patients developing MACE during follow-up 263

The atherogenic index of plasma and carotid atherosclerosis in a community population: a population-based cohort study in China

2026-11-13T05:07:38.642Z

Cohort study · Cardiovasc Diabetol, 2023. CA, increased CIMT and plaques — Per 1-SD increase in AIP: OR 1.06 (95% CI 1.04, 1.08); CA; adjusted for traditional risk factors

Triglyceride-glucose index, symptomatic intracranial artery stenosis and recurrence risk in minor stroke patients with hypertension

2026-11-13T05:07:38.642Z

Cohort study · Cardiovasc Diabetol, 2023. Stroke recurrence, 90 days — Q4 TyG vs Q1 TyG: HR 2.02 (95% CI 1.07-3.84); p = 0.025; adjusted for confounders

U-shaped association between the triglyceride–glucose index and atrial fibrillation incidence in a general population without known cardiovascular disease

2026-11-13T05:07:38.642Z

Cohort study · Cardiovasc Diabetol, 2023. Incident AF, median follow-up 24.26 years — TyG <8.80 vs TyG 8.80-9.20: aHR 1.15 (95% CI 1.02, 1.29)

Mendelian randomisation reveals Sodium-glucose Cotransporter-1 inhibition's potential in reducing Non-Alcoholic Fatty Liver Disease risk

2026-11-13T04:50:20.257Z

Research article · Eur J Endocrinol, 2023. NAFLD risk: OR per 1 mmol/mol HbA1c reduction via genetically proxied SGLT-1i 0.36 (95% CI 0.15, 0.87; P = .023)

Effects of Statins on Fat Oxidation Improvements After Aerobic Exercise Training

2026-11-13T04:45:48.554Z

Cohort study · J Clin Endocrinol Metab, 2022. Change in FOMAX after training: Statin 0.06 ± 0.08 g·min-1; 95% CI 0.03-0.08 · Control 0.05 ± 0.09 g·min-1; 95% CI 0.03-0.07

Glucagon-like Peptide-2 Acutely Enhances Chylomicron Secretion in Humans Without Mobilizing Cytoplasmic Lipid Droplets

2026-11-13T04:45:48.554Z

Mechanistic study · J Clin Endocrinol Metab, 2022. Plasma TG increased with GLP-2 46% (P = 0.009)

Impact of Thyroid Function on the Prevalence and Mortality of Metabolic Dysfunction-Associated Fatty Liver Disease

2026-11-13T04:45:48.554Z

Cross-sectional study · J Clin Endocrinol Metab, 2023. MAFLD prevalence and all-cause and cardiovascular mortality — Low thyroid function: OR 1.27; MAFLD; independent association

Community Social Capital and Population Health Outcomes

2026-11-13T01:11:44.770Z

Cross-sectional study · JAMA Netw Open, 2023. Association of social capital measures with population health outcomes (per 1% increase): Economic connectedness: diabetes prevalence -0.63% (95% CI, -0.67% to -0.60%)

Effects of obstructive sleep apnea on non-alcoholic fatty liver disease in patients with obesity: a systematic review

2026-11-13T01:05:47.943Z

Meta-analysis · Int J Obes (Lond), 2023. OSA-related predictors of NAFLD: In most studies, significant correlations between OSA, OSA-related outcomes and NAFLD